Linked Data API

Show Search Form

Search Results

1132764
star this property registered interest false more like this
star this property date less than 2019-06-18more like thismore than 2019-06-18
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
unstar this property question text What progress the Government has made on making medical cannabis available to people who need it. more like this
unstar this property tabling member constituency Gower more like this
star this property tabling member printed
Tonia Antoniazzi more like this
star this property uin 911421 more like this
unstar this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-06-18more like thisremove minimum value filter
star this property answer text <p>The Government acted swiftly to change the law and those patients for whom it is clinically appropriate can be prescribed medicinal cannabis. It is a clinical decision whether to prescribe, and prescriptions of medicinal cannabis are available, and being issued where it is judged clinically appropriate for the patient.</p><p /><p /> more like this
star this property answering member constituency West Suffolk more like this
star this property answering member printed Matt Hancock more like this
star this property question first answered
less than 2019-06-18T16:50:49.883Zmore like thismore than 2019-06-18T16:50:49.883Z
star this property answering member
4070
star this property label Biography information for Matt Hancock more like this
star this property tabling member
4623
unstar this property label Biography information for Tonia Antoniazzi more like this
1132025
star this property registered interest false more like this
star this property date less than 2019-06-13more like thismore than 2019-06-13
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
unstar this property question text To ask the Secretary of State for Health and Social Care, how and by whom medical cannabis was produced in the UK before its legalisation. more like this
unstar this property tabling member constituency Central Ayrshire more like this
star this property tabling member printed
Dr Philippa Whitford more like this
star this property uin 264425 more like this
unstar this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-06-18more like thisremove minimum value filter
star this property answer text <p>Prior to the change of the law on 1 November 2018, only cannabis-based products that had been given a marketing authorisation (product licence) by the medicines regulators, the Medicines and Healthcare products Regulatory Agency (MHRA) or European Medicines Agency could be prescribed. Before issuing a marketing authorisation the MHRA accesses all the available evidence on efficacy and safety arising out of pre-clinical research and clinical trials and evidence and information supplied by the manufacturer. The regulators also inspect the factory where the medicine is to be made, to make sure that supplies will be of a uniformly and consistently high standard.</p><p> </p><p>The following cannabis-based products and related products received a marketing authorisation in the United Kingdom/European Union before 1 November 2018:</p><p> </p><p>- Sativex - (produced by GW Pharmaceuticals) containing tetrahydrocannabinol (THC) and cannabidiol - holds a licence for spasticity in multiple sclerosis; and</p><p>- Nabilone - (multiple manufacturers) which contains a synthetic, non-natural cannabinoid which mimics THC, holds a marketing authorisation for nausea and vomiting caused by chemotherapy.</p><p> </p><p>In addition, Epidiolex (also produced by GW Pharmaceuticals from cannabis) for two severe forms of intractable epilepsy (Lennox-Gastaut Syndrome or Dravet Syndrome), is currently being considered for a marketing authorisation by the European Medicines Agency.</p><p> </p><p>The change in the law allows the prescription, by specialist doctors on the General Medical Council’s Specialist Register, of cannabis-based products that have not been through this rigorous process but that meet certain quality standards in cases where all licensed products have been considered and discounted and it is in the best interest of the patient. It also makes</p><p>it easier and will incentivise further research into the potential health benefits of cannabis-based products and the development of further licensed products for more routine use in the health service.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-06-18T16:31:54.17Zmore like thismore than 2019-06-18T16:31:54.17Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4385
unstar this property label Biography information for Dr Philippa Whitford more like this
1131293
star this property registered interest false more like this
star this property date less than 2019-06-11more like thismore than 2019-06-11
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
unstar this property question text To ask the Secretary of State for Health and Social Care, how many companies are licensed to sell cannabis products to the NHS. more like this
unstar this property tabling member constituency Ross, Skye and Lochaber more like this
star this property tabling member printed
Ian Blackford more like this
star this property uin 263171 more like this
unstar this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-06-19more like thismore than 2019-06-19
star this property answer text <p>Any company meeting the standards for the manufacture of unlicensed medicinal products, can supply cannabis-based products for medicinal use.</p><p> </p><p>Cannabis-based products for medicinal use are Schedule 2 controlled drugs under the Misuse of Drugs Regulations 2001, which means that manufacturers, importers and distributors of these products must hold valid Home Office and Medicines and Healthcare products Regulatory Agency (MHRA) licences for the relevant activities which will include possession, supply and production of controlled drugs. Where products are sourced from abroad, importers must obtain an import licence from the Home Office and non-objection to import from the MHRA for each individual import of a controlled drug.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p><p><strong> </strong></p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-06-19T09:39:54.803Zmore like thismore than 2019-06-19T09:39:54.803Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4390
unstar this property label Biography information for Ian Blackford more like this
1131321
star this property registered interest false more like this
star this property date less than 2019-06-11more like thismore than 2019-06-11
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cannabis: Medical Treatments remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
unstar this property question text To ask the Secretary of State for Health and Social Care, what progress he has made on ensuring that medical cannabis is available to people who need it. more like this
unstar this property tabling member constituency Birkenhead more like this
star this property tabling member printed
Frank Field more like this
star this property uin 263063 more like this
unstar this property answer
answer
unstar this property is ministerial correction false more like this
unstar this property date of answer less than 2019-06-19more like thismore than 2019-06-19
star this property answer text <p>The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s ‘Specialist Register’ to prescribe cannabis-based products for medicinal use, where clinically appropriate and in the best interest of patients.</p><p>Interim clinical guidance has been issued by the Royal College of Physicians, the British Paediatric Neurology Association and the Association of British Neurologists to support doctors looking to prescribe cannabis-based products. The National Institute for Health and Care Excellence (NICE) has been commissioned to develop updated clinical guidance on the prescribing of cannabis-based medicinal products, which will be published by October 2019. It will be based on the best available international evidence and will have been produced using NICE’s world-renowned process for delivering such guidance.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-06-19T14:21:18.483Zmore like thismore than 2019-06-19T14:21:18.483Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
478
unstar this property label Biography information for Frank Field more like this